pyrazines has been researched along with Hyperlipoproteinemia Type IV in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hortobágyi, J; Schneider, I; Zahorcsek, Z | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Tornvall, P; Walldius, G | 1 |
| Nikkilä, EA; Taskinen, MR | 1 |
| Avogaro, P; Crepaldi, G; Descovich, GC; Di Perri, T; Musatti, L; Postiglione, A; Sirtori, CR; Strano, A; Ventura, S | 1 |
| Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A | 1 |
4 trial(s) available for pyrazines and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
Topics: Adult; Blood Glucose; Female; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrazines | 1991 |
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
Topics: Adult; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Humans; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins, HDL; Male; Middle Aged; Phospholipids; Pyrazines; Random Allocation; Triglycerides | 1988 |
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrazines; Triglycerides | 1988 |
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Cholesterol; Clofibrate; Female; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Pyrazines; Triglycerides | 1985 |
2 other study(ies) available for pyrazines and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
[Successful treatment of eruptive xanthomatosis with the antilipemic agents acipimox].
Topics: Combined Modality Therapy; Diet, Fat-Restricted; Humans; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Skin; Xanthomatosis | 1995 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |